ロード中...
Preclinical evaluation of the PARP inhibitor BMN-673 for the treatment of ovarian clear cell cancer
PURPOSE: To determine if models of ovarian clear cell carcinomas (OCCCs) harbouring defects in homologous recombination (HR) DNA repair of double strand breaks (DSBs) are sensitive to cisplatin and/or PARP inhibition. EXPERIMENTAL DESIGN: The HR status of 12 OCCC cell lines was determined using RAD5...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2016
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5351612/ https://ncbi.nlm.nih.gov/pubmed/28002809 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.14011 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|